In his session, Menzies-Gow discussed the radical change the severe eosinophilic asthma field has seen over the past decade. When he first began working in the therapy area, asthma was seen as one diagnosis, and healthcare professionals (HCPs) knew little about what was causing the disease on an individual basis. Ten years later, we can now endotype asthma so patients can be given the right treatment, at the right time, to significantly improve their quality of life.

But if patients present with more than one cause of disease, can they be given more than one biologic? While there are currently significant concerns regarding safety and cost, Menzies-Gow argued that with so many new, broader treatments on the horizon such as small molecules, HCPs may eventually be able to safely combine different therapies to provide a more personalised approach to care.

Whilst Prof. Menzies-Gow focused on severe asthma, our second sessions with Prof. Barnes focused primarily on finding new ways to treat mild and moderate asthma. Thanks to the SYGMA trials, there is now strong evidence for using anti-inflammatory inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) combination inhalers as both maintenance and reliever therapy (MART). When used as reliever therapy, combination inhalers were shown to give patients greater control over their asthma, with a reduced exacerbation risk in comparison to short-acting beta agonists (SABAs).1,2 Barnes argued that anti-inflammatory MART can therefore provide a highly effective treatment regime for patients with the convenience of a single inhaler; representing the next stage in mild and moderate asthma management.